View Older Stories View More Recent Stories

Oct 13, 2022 04:00PM BridgeBio Pharma Inc. (BBIO) Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program
Oct 13, 2022 04:00PM BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
Oct 13, 2022 04:00PM BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
Oct 11, 2022 07:30AM BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
Oct 11, 2022 07:30AM BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
Oct 7, 2022 07:30AM BridgeBio Pharma (BBIO) to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium
Oct 7, 2022 07:30AM BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium
Oct 7, 2022 07:30AM BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium
Sep 20, 2022 07:31AM BridgeBio Pharma Inc. (BBIO) and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY
Sep 20, 2022 07:30AM BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Sep 20, 2022 07:30AM BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Sep 6, 2022 07:30AM BridgeBio Pharma to Participate in September Investor Events
Sep 6, 2022 07:30AM BridgeBio Pharma to Participate in September Investor Events
Aug 18, 2022 07:30AM BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)
Aug 18, 2022 07:30AM BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)
Aug 10, 2022 07:31AM BridgeBio Pharma (BBIO), Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Aug 10, 2022 07:30AM BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Aug 10, 2022 07:30AM BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Aug 10, 2022 07:30AM BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Aug 4, 2022 07:30AM BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update
Aug 4, 2022 07:30AM BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update
Jul 26, 2022 07:30AM BridgeBio Pharma Inc. (BBIO) Reports Positive Interim Results from a Phase 2 Trial of Infigratinib
Jul 26, 2022 07:30AM BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years o
Jul 26, 2022 07:30AM BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years o
Jul 25, 2022 07:31AM BridgeBio (BBIO) and Sentynl Get Positive CHMP Opinion for NULIBRY
Jul 25, 2022 07:30AM BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Jul 25, 2022 07:30AM BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Jul 25, 2022 07:30AM BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Jul 21, 2022 07:30AM BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases
Jul 21, 2022 07:30AM BridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley’s Bakar BioEnginuity Hub
Jul 21, 2022 07:30AM BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases
Jul 21, 2022 07:30AM BridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley’s Bakar BioEnginuity Hub
Jun 27, 2022 07:30AM BridgeBio Pharma Inc. (BBIO) Reports Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711
Jun 27, 2022 07:30AM BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Form
Jun 27, 2022 07:30AM BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Form
Jun 22, 2022 07:31AM BridgeBio Pharma Inc. (BBIO) Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
Jun 22, 2022 07:30AM BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
Jun 22, 2022 07:30AM BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
Jun 13, 2022 08:20AM BridgeBio Pharma Inc. (BBIO) Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1
Jun 13, 2022 08:00AM BridgeBio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Jun 13, 2022 08:00AM BridgeBio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Jun 10, 2022 07:30AM BridgeBio Pharma's (BBIO) Venthera Presents Preliminary Results from Clinical Trial of VT30
Jun 10, 2022 07:30AM BridgeBio Pharma Affiliate Venthera Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations
Jun 10, 2022 07:30AM BridgeBio Pharma Affiliate Venthera Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations
Jun 9, 2022 07:30AM BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference
Jun 9, 2022 07:30AM BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference
Jun 6, 2022 07:30AM BridgeBio Pharma to Participate in June Investor Events
Jun 6, 2022 07:30AM BridgeBio Pharma to Participate in June Investor Events
May 26, 2022 01:00PM BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias
May 26, 2022 01:00PM BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias
View More Recent Stories View Older Stories